Astellas’ fezolinetant fails to meet pre-defined endpoints for efficacy in Moonlight clinical… EP News Bureau Mar 18, 2022 Based on the 12-week data analysis in 302 participants, fezolinetant 30 mg once daily (QD) in women in China, Korea and Taiwan did…
